Search results
Showing 1351 to 1365 of 8314 results
Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)
Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events after myocardial infarction in adults.
Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)
Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy.
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)
Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive breast cancer that is locally advanced, inflammatory, or early-stage with a high risk of recurrence, in adults.
Evidence-based recommendations on bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for treating advanced or metastatic renal cell carcinoma in adults.
Spesolimab for treating generalised pustular psoriasis flares (TA1070)
Evidence-based recommendations on spesolimab (Spevigo) for treating generalised pustular psoriasis flares in adults.
Pemetrexed for the first-line treatment of non-small-cell lung cancer (TA181)
Evidence-based recommendations on pemetrexed for untreated non-small-cell lung cancer in adults.
Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)
Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.
Topotecan for the treatment of relapsed small-cell lung cancer (TA184)
Evidence-based recommendations on topotecan for treating relapsed small-cell cancer in adults.
View recommendations for TA184Show all sections
Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)
Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma in adults.
Infliximab and adalimumab for the treatment of Crohn's disease (TA187)
Evidence-based recommendations on infliximab (Remicade) and adalimumab (Humira) for treating severe active Crohn's disease in adults.
NICE is unable to make a recommendation on tislelizumab (Tevimbra) for treating advanced non-small-cell lung cancer after platinum-based chemotherapy in adults. This is because BeiGene withdrew its evidence submission.
Show all sections
Sections for TA1072
Evidence-based recommendations on structural neuroimaging in people with first-episode psychosis.
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (TA440)
Evidence-based recommendations on pegylated liposomal irinotecan (Onivyde) for treating pancreatic cancer in adults.
Evidence-based recommendations on efanesoctocog alfa (Altuvoct) for treating and preventing bleeding episodes in haemophilia A in people 2 years and over.
Evidence-based recommendations on rituximab for treating relapsed or refractory stage 3 or 4 follicular non-Hodgkin's lymphoma in adults.